Equities research analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post $1.54 billion in sales for the current quarter, Zacks reports. Eight analysts have provided estimates for Regeneron Pharmaceuticals’ earnings. The highest sales estimate is $1.68 billion and the lowest is $1.44 billion. Regeneron Pharmaceuticals posted sales of $1.32 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 16.7%. The company is expected to report its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year sales of $1.54 billion for the current financial year, with estimates ranging from $6.08 billion to $6.94 billion. For the next financial year, analysts anticipate that the company will post sales of $7.14 billion per share, with estimates ranging from $6.56 billion to $7.92 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.18 by $1.05. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The business’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.04 EPS.
Several equities research analysts have issued reports on REGN shares. BTIG Research reissued a “buy” rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. Piper Jaffray Companies reissued a “buy” rating and issued a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Citigroup reissued a “buy” rating and issued a $480.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. Argus lowered their price target on shares of Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating on the stock in a report on Thursday, December 28th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $522.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 7th. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $450.65.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 10.80% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of the business. Global X MANAGEMENT CO LLC grew its holdings in Regeneron Pharmaceuticals by 10.7% during the 3rd quarter. Global X MANAGEMENT CO LLC now owns 1,334 shares of the biopharmaceutical company’s stock worth $596,000 after acquiring an additional 129 shares during the last quarter. King Luther Capital Management Corp lifted its position in Regeneron Pharmaceuticals by 21.3% during the 3rd quarter. King Luther Capital Management Corp now owns 825 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 145 shares during the period. Advantus Capital Management Inc lifted its position in Regeneron Pharmaceuticals by 1.9% during the 3rd quarter. Advantus Capital Management Inc now owns 7,885 shares of the biopharmaceutical company’s stock valued at $3,526,000 after purchasing an additional 148 shares during the period. BTIM Corp. lifted its position in Regeneron Pharmaceuticals by 14.3% during the 4th quarter. BTIM Corp. now owns 1,200 shares of the biopharmaceutical company’s stock valued at $451,000 after purchasing an additional 150 shares during the period. Finally, Nomura Asset Management Co. Ltd. lifted its position in Regeneron Pharmaceuticals by 0.9% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 17,010 shares of the biopharmaceutical company’s stock valued at $7,606,000 after purchasing an additional 151 shares during the period. 64.67% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded down $5.53 during trading on Friday, reaching $317.51. 926,615 shares of the company’s stock traded hands, compared to its average volume of 1,072,069. The company has a market cap of $34,200.00, a price-to-earnings ratio of 24.16, a PEG ratio of 1.04 and a beta of 1.47. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. Regeneron Pharmaceuticals has a 12-month low of $313.53 and a 12-month high of $543.55.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.